4ú Feabhra 2022: San India, is féidir le hailse éifeachtaí sóisialta agus eacnamaíocha tromchúiseacha a bheith aici, agus go hiondúil bíonn bochtanas teaghlaigh agus éagóir sa tsochaí mar thoradh air. Sa tír seo atá óg go déimeagrafach, tá na rátaí minicíochta ailse arna choigeartú de réir aoise a thuairiscítear fós measartha íseal. I ndaonra de 1.3 billiún duine, aimsítear beagán níos mó ná 1 milliún cás nua ailse gach bliain. I dtéarmaí aois-choigeartaithe, léiríonn sé seo thart ar an ceathrú cuid de mhinicíocht na bhfear agus na mban a chonacthas in Iarthar na hEorpa. Ar an láimh eile, bhí ailse freagrach as thart ar 600000-700000 bás san India in 2012.
De réir anailíse Staidéar Domhanda Ualach Galar 2019 an staidéir IHME, níl an pictiúr difriúil ar fud an domhain. In 2019, sháraigh líon na gcásanna ailse nua 23 milliún, suas ó 18.7 milliún in 2010. In 2019, bhí 10 milliún bás ailse, suas ó 8.29 milliún in 2010. Léiríonn na torthaí seo méadú 20.9 faoin gcéad agus 26.3 faoin gcéad, faoi seach. .
In both developing and developed countries, cancer is a leading cause of morbidity and mortality. The majority of the population in many low- and middle-income nations, including India, does not have access to a well-organized and well-regulated cancer care system. When a person is diagnosed with cancer, they are often forced to spend a lot of money on their own health. Such expenses can push entire families into poverty and, when paired with a lack of what are considered acceptable services, can jeopardize social stability. It can be easily said that cancer treatment in India is still in a nascent stage and huge development is required in this field.
There are two major problems cancer patients and their family members face when someone is diagnosed with cancer. One is, where will they get the best and most appropriate treatment, and two, how much money will be required for treatment? Second is the most important question, as the general population in India is still devoid of health insurance. We at CancerFax addresses both these problems. We help cancer patients find most appropriate and economical cancer treatment in India and abroad. CancerFax is working with more than 100 top cancer hospitals in 10 countries like Dana-Farber, Mayo Clinic, Boston Children’s Hospital, Sheba, Asan, Apollo, BLK, Artemis to name a few.
CAR T-Cell therapy is a breakthrough treatment for some kinds of lymphoma, leukemia and multiple myeloma. CancerFax helps patients enroll for Teiripe CAR T-Cell treatment in the USA, Israel and China. Many patients who had previously relapsed blood tumors had no evidence of cancer after CAR T-Cell therapy. It has also aided in the rehabilitation of patients who have previously failed to respond to most traditional cancer therapies. There are more than 300 ongoing clinical trials in the world’s leading cancer centers on this therapy. CAR T-Cell therapy in India is available as clinical trials now. I hope it will be available for commercial treatment very soon.
